Man Group PLC Incyte Corp Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Incyte Corp stock. As of the latest transaction made, Man Group PLC holds 804,952 shares of INCY stock, worth $57.7 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

804,952

Previous 786,566 2.34%

Holding current value

$57.7 Million

Previous $47.7 Million 11.59%

% of portfolio

0.15%

Previous 0.13%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $1.05 Million - $1.26 Million	18,386 Added 2.34%	804,952 $53.2 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $67.2 Million - $83.6 Million	-1,312,090 Reduced 62.52%	786,566 $47.7 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $15.7 Million - $18.5 Million	-277,778 Reduced 11.69%	2,098,656 $120 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $8.09 Million - $9.96 Million	-155,184 Reduced 6.13%	2,376,434 $149 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $65.9 Million - $75.2 Million	1,140,682 Added 82.01%	2,531,618 $146 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $34.8 Million - $43.1 Million	570,712 Added 69.58%	1,390,936 $86.6 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $39.4 Million - $48.2 Million	560,405 Added 215.69%	820,224 $59.3 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $35.4 Million - $44.3 Million	-526,989 Reduced 66.98%	259,819 $20.9 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $32.6 Million - $40.8 Million	492,998 Added 167.79%	786,808 $52.4 Million
Q2 2022 Aug 15, 2022	BUY	$66.18 - $83.18 $5.23 Million - $6.58 Million	79,060 Added 36.81%	293,810 $22.3 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $39.2 Million - $47.3 Million	-593,355 Reduced 73.43%	214,750 $17.1 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $37 Million - $43.3 Million	584,403 Added 261.24%	808,105 $59.3 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $14 Million - $17.2 Million	204,291 Added 1052.45%	223,702 $15.4 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1.22 Million - $1.33 Million	15,239 Added 365.27%	19,411 $1.63 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $108,480 - $143,413	1,427 Added 51.99%	4,172 $339,000
Q4 2020 Feb 16, 2021	SELL	$80.74 - $97.7 $1.14 Million - $1.38 Million	-14,103 Reduced 83.71%	2,745 $239,000
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $16.7 Million - $21.5 Million	-196,042 Reduced 92.09%	16,848 $1.51 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $48.8 Million - $71.7 Million	-658,157 Reduced 75.56%	212,890 $22.1 Million
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $10.5 Million - $14.3 Million	166,138 Added 23.57%	871,047 $63.8 Million
Q4 2019 Feb 18, 2020	BUY	$73.04 - $95.72 $38.1 Million - $49.9 Million	521,341 Added 284.0%	704,909 $61.6 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $7.28 Million - $8.65 Million	99,920 Added 119.45%	183,568 $13.6 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $5.58 Million - $6.74 Million	75,936 Added 984.65%	83,648 $7.11 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $1.98 Million - $2.74 Million	-31,126 Reduced 80.14%	7,712 $663,000
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $128,875 - $154,077	2,203 Added 6.01%	38,838 $2.47 Million
Q3 2018 Nov 14, 2018	BUY	$61.75 - $74.23 $1.42 Million - $1.7 Million	22,938 Added 167.47%	36,635 $2.53 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $264,514 - $365,061	4,347 Added 46.49%	13,697 $917,000
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $776,611 - $944,163	9,350 New	9,350 $779,000

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account